A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease

Clinica Chimica Acta

Volumn 398, Issue 1-2, 2008, Pages 34-38

  Nakagawa, Takehiro ^a   Muramoto, Yosuke ^a   Hori, Masaharu ^a   Mihara, Shuichi ^b   Marubayashi, Toru ^b   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

Author keywords

Fatty liver disease; Genetic polymorphisms; Haptoglobin; NAFLD; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; HAPTOGLOBIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DISEASE PREDISPOSITION; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR;

ALCOHOL DRINKING; ALLELES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; FERRITINS; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 54049126869     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.08.004     Document Type: Article

References (27)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Osterreicher C.H., and Brenner D.A. The genetics of nonalcoholic fatty liver disease. Ann Hepatol 6 (2007) 83-88
3. Swinkels D.W., Janssen M.C., Bergmans J., and Marx J.J. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 52 (2006) 950-968
4. Valenti L., Fracanzani A.L., Dongiovanni P., et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102 (2007) 1251-1258
5. Zelber-Sagi S., Nitzan-Kaluski D., Halpern Z., and Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferretin concentrations. J Hepatol 46 (2007) 700-707
6. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42 (1996) 1589-1600
7. Carter K., and Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 29 (2007) 92-110
8. Van Vlierberghe H., Langlois M., and Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 345 (2004) 35-42
9. Hori M., Oniki K., Ueda K., et al. Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against Type 2 diabetes in Japanese. Pharmacogenomics 8 (2007) 1307-1314
10. Jimba S., Nakagami T., Takahashi M., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22 (2005) 1141-1145
11. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care 26 Suppl 1 (2003) S5-S20
12. Nishizono I., Iida S., Suzuki N., et al. Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers. Clin Chem 37 (1991) 1639-1644
13. Koch W., Latz W., Eichinger M., et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48 (2002) 1377-1382
14. Langlois M.R., Martin M.E., Boelaert J.R., et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem 46 (2000) 1619-1625
15. Levy A.P. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther 112 (2006) 501-512
16. Milman U., Blum S., Shapira C., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 28 (2008) 341-347
17. Louagie H.K., Brouwer J.T., Delanghe J.R., De Buyzere M.L., and Leroux-Roels G.G. Haptoglobin polymorphism and chronic hepatitis C. J Hepatol 25 (1996) 10-14
18. Zipprich B., Giebelmann R., Tolani K., et al. Haptoglobin type and liver disease. Hepato-gastroenterol 33 (1986) 196-198
19. Bugianesi E., Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
20. Forouhi N.G., Harding A.H., Allison M., et al. Elevated serum ferretin concentrations predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50 (2007) 949-956
21. Jehn M.L., Guallar E., Clark J.M., et al. A prospective study of plasma ferretin concentration and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 165 (2007) 1047-1054
22. Facchini F.S., Hua N.W., and Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 931-939
23. Fernandez-Real J.M., Lopez-Bermejo A., and Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin chem 51 (2005) 1201-1205
24. Alla V., and Bonkovsky H.L. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 25 (2005) 461-472
25. Danesh J., and Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99 (1999) 852-854
26. Trombini P., and Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol 46 (2007) 549-552
27. Braeckman L., De Bacquer D., Delanghe J., Claeys L., and De Backer G. Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143 (1999) 383-388